Yahoo Finance5d
Antibiotics Market Expected To Reach USD 72.9 Billion by 2032, Growing at CAGR 4.1% | Abbott Laboratories, Astellas Pharma, Bayer
This anticipated expansion reflects a strong CAGR of 4.1% from 2024 to 2032. The antibiotics market is driven by rising ...
The Pharma Letter22h
Kerendia: Bayer’s big opportunity to deliver for millions of patients, across indications
An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...
Pharmabiz6h
Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure
Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...
FiercePharma4d
Bayer brings heart health message to Super Bowl, warning millennials to open their eyes to risks
Bayer is worried about your heart health. | Older millennials, take note: Bayer is worried about your heart health. The drugmaker set out its concerns in an ad for aspirin, showing how people are ...
Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...
MM&M4d
Bayer’s Super Bowl ad tackles denial in heart disease
In its See Your Risks campaign, Bayer takes aim at denial among millennials and Gen Xers when it comes to heart disease. To ...
Pharmabiz2d
BridgeBio Pharma announces EU grants marketing authorization to Beyonttra to treat transthyretin amyloidosis in adults with cardiomyopathy
Palo Alto, California Thursday, February 13, 2025, 12:00 Hrs [IST] ...
pharmaphorum2d
A history of Bayer
Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company, it’s a good idea to get your head around the different names ...
J.P. Morgan Reaffirms Their Hold Rating on Bayer (0P6S)
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €25.00. The ...